Loading clinical trials...
Loading clinical trials...
Open Label, Phase 2, Single-Arm Study of Selinexor, Daratumumab, Carfilzomib and Dexamethasone for High-Risk, Relapsed and Relapsed/Refractory Multiple Myeloma Patients Who Have Received 1 - 3 Prior Lines of Therapy
Conditions
Interventions
Carfilzomib
Daratumumab
+3 more
Locations
4
United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
State University of New York Upstate Medical University
Syracuse, New York, United States
UNC Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Carolinas Medical Center/Levine Cancer Institute
Charlotte, North Carolina, United States
Start Date
December 8, 2022
Primary Completion Date
September 30, 2024
Completion Date
December 30, 2027
Last Updated
September 26, 2024
NCT05312255
NCT04508790
NCT04640779
NCT04850599
NCT05288062
NCT03015792
Lead Sponsor
Academic and Community Cancer Research United
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions